by Jay Grisolano
| Jan 20, 2017
Oncology Conference Insight: ASCO GI 2017 --- Before Cyramza® (ramucirumab, Eli Lilly and Co) was approved by the FDA in 2014, there were no targeted therapy regimens approved for use in relapsed/refractory gastric cancer. Cyramza’s approval as a monotherapy or in combination with paclitaxel after prior fluoropyrimidine- or platinum-containing systemic therapy was based on the positive results of two Phase III studies in relapsed gastric patients.